XM does not provide services to residents of the United States of America.
B
B

Biogen

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

What to Watch in the Day Ahead - Wednesday, September 4

What to Watch in the Day Ahead - Wednesday, September 4 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT U.S. investors will look forward to the Labor Department's Job Openings and Labor Turnover Survey, or JOLTS report.
B
G
P
D

U.S. STOCKS NetEase, Wolfspeed, B. Riley

BUZZ-U.S. STOCKS ON THE MOVE-NetEase, Wolfspeed, B. Riley Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes fell in volatile trading on Thursday, as rising Treasury yields pressured stocks ahead of Federal Reserve Chair Jerome Powell's speech at Jackson Hole that could offer clues on the possibility of a rate cut next month.
A
B
N
S
U
U
U
E
S
A

U.S. STOCKS Evogene, Stryker, Opera

BUZZ-U.S. STOCKS ON THE MOVE-Evogene, Stryker, Opera Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes fell in volatile trading on Thursday, as rising Treasury yields pressured stocks ahead of Federal Reserve Chair Jerome Powell's speech at Jackson Hole that could offer clues on the possibility of a rate cut next month.
A
B
B
I
N
U
U
U
E
S
A

Biogen falls after new Alzheimer's drug deemed costly by UK pricing watchdog

BUZZ-Biogen falls after new Alzheimer's drug deemed costly by UK pricing watchdog ** Shares of Biogen BIIB.O fall 1.3% to $203.45 ** UK health regulator has approved BIIB and partner Eisai's 4523.T drug Leqembi, making it the first treatment for Alzheimer's disease licensed for use in the country ** However, the UK cost effectiveness body, the Nati
B

New Alzheimer's drug deemed too costly for UK's state-run health service

UPDATE 5-New Alzheimer's drug deemed too costly for UK's state-run health service Eisai-Biogen drug first treatment to slow Alzheimer's course UK draft guidance on cost a blow after slow take-up in U.S. Adds Biogen shares in paragraph 10 and analyst comment in paragraph 19 By Maggie Fick Aug 22 (Reuters) - Alzheimer's patients in Britain's state-run health service are unlikely to get access to Eisai 4523.T and Biogen's BIIB.O new Leqembi drug, after it was approved on Thursday by the country's r
B

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.